Journal ArticleDOI
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Roger Stupp,Pierre Yves Dietrich,Sandrine Ostermann Kraljevic,Alessia Pica,Ivan Maillard,Phillipe Maeder,Reto Meuli,Robert C. Janzer,Gianpaolo Pizzolato,Raymond Miralbell,F. Porchet,Luca Regli,Nicolas de Tribolet,René O. Mirimanoff,Serge Leyvraz +14 more
TLDR
This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.Abstract:
PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM). This phase II study was performed to determine the safety, tolerability, and efficacy of concomitant radiation plus temozolomide therapy followed by adjuvant temozolomide therapy in patients with newly diagnosed GBM. PATIENTS AND METHODS: Sixty-four patients were enrolled onto this open-label, phase II trial. Temozolomide (75 mg/m2/d × 7 d/wk for 6 weeks) was administered orally concomitant with fractionated radiotherapy (60 Gy total dose: 2 Gy × 5 d/wk for 6 weeks) followed by temozolomide monotherapy (200 mg/m2/d × 5 days, every 28 days for six cycles). The primary end points were safety and tolerability, and the secondary end point was overall survival. RESULTS: Concomitant radiation plus temozolomide therapy was safe and well tolerated. Nonhematologic toxicities were rare and mild to moderate in severity. During t...read more
Citations
More filters
Journal ArticleDOI
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM)
Carmen Balana,Antonio Lopez-Pousa,Alfonso Berrocal,Ricardo Yaya-Tur,Ana Herrero,Jose-Luis García,Javier Martin-Broto,Manuel Benavides,Miguel Cerdá-Nicolás,R. Ballester,Josep Balart,Jaume Capellades +11 more
TL;DR: This regimen has significant activity, as it induces objective responses even in biopsy-only patients, appearing to improve their median survival, and a better combination schedule is needed to improve the toxicity profile.
Journal ArticleDOI
Mechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme
Tamar Fisher,Gil Galanti,Gad Lavie,Jasmine Jacob-Hirsch,Iris Kventsel,Sharon Zeligson,Robert E. Winkler,Amos J. Simon,Ninette Amariglio,Gideon Rechavi,Amos Toren +10 more
TL;DR: It is proposed that treatment with TMZ be supplemented with either an antibody to VEGF or down-regulators of HIF-1&agr; to improve clinical results of TMZ in the treatment of GBM.
Journal ArticleDOI
Therapeutic advances in malignant glioma: current status and future prospects.
TL;DR: The concepts of pseudoprogression and pseudoresponse are introduced, which are new imaging correlates that have significant impact on understanding of the disease.
Journal ArticleDOI
Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Barbara Fazeny-Dörner,Mario Veitl,Catharina Wenzel,Maria Piribauer,Karl Rössler,Karin Dieckmann,Karl Ungersböck,Christine Marosi +7 more
TL;DR: It is concluded that the D/F combination is a well-tolerated second-line regimen and can be administered in a complete outpatient setting and shows efficacy even in nitrosourea-pretreated patients and justifies further investigation.
Book ChapterDOI
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
TL;DR: Given that the EORTC-based regimen represents an incremental improvement in the standard of care, rather than a truly curative solution for most patients, further efforts must be expended to identify novel therapeutic approaches.
References
More filters
Journal ArticleDOI
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial
Walker,Eben Alexander,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Norrell Ha,Owens G,Joseph Ransohoff,Charles B. Wilson,Gehan Ea,Strike Ta +11 more
TL;DR: An analysis of prognostic factors indicates that the initial performance status, age, the use of only a surgical biopsy, parietal location, the presence of seizures, or the involvement of cranial nerves II, III, IV, and VI are all of significance.
Journal ArticleDOI
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Walker,Sylvan B. Green,David P. Byar,Eben Alexander,Batzdorf U,Brooks Wh,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Owens G,Ransohoff J nd,Robertson Jt,W. R. Shapiro,Smith Kr,Charles B. Wilson,Strike Ta +16 more
TL;DR: It is suggested that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.
Journal ArticleDOI
The new WHO classification of brain tumours.
TL;DR: The new edition of the World Health Organization (WHO) book on ‘Histological Typing of Tumours of the Central Nervous System’ reflects the progress in brain tumour classification which has been achieved since publication of the first edition in 1979.
Journal ArticleDOI
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Henry Brem,Steven Piantadosi,Steven Piantadosi,Peter C. Burger,Michael D. Walker,Robert G. Selker,N. A. Vick,K Black,Michael B. Sisti,Steven Brem,G Mohr,P Muller,R Morawetz,S.C Schold +13 more
TL;DR: Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. J. Fischbach,C. H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: This study of malignant glioma patients used a non-parametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration and permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more